DarioHealth Stock Forecast, Price & News

DarioHealth (NASDAQ:DRIO) Frequently Asked Questions

Is DarioHealth a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DarioHealth stock.
View analyst ratings for DarioHealth or view top-rated stocks.

How has DarioHealth's stock been impacted by Coronavirus?

DarioHealth's stock was trading at $6.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DRIO stock has increased by 115.8% and is now trading at $14.87.
View which stocks have been most impacted by COVID-19.

When is DarioHealth's next earnings date?

DarioHealth is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for DarioHealth.

How were DarioHealth's earnings last quarter?

DarioHealth Corp. (NASDAQ:DRIO) announced its quarterly earnings data on Monday, November, 15th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.94) by $0.24. DarioHealth had a negative net margin of 391.42% and a negative trailing twelve-month return on equity of 71.45%. During the same period in the prior year, the firm earned ($0.71) EPS.
View DarioHealth's earnings history.

What price target have analysts set for DRIO?

6 equities research analysts have issued 1-year price objectives for DarioHealth's stock. Their forecasts range from $12.75 to $35.00. On average, they expect DarioHealth's stock price to reach $26.35 in the next year. This suggests a possible upside of 77.2% from the stock's current price.
View analysts' price targets for DarioHealth or view top-rated stocks among Wall Street analysts.

Who are DarioHealth's key executives?

DarioHealth's management team includes the following people:

• Erez Raphael, Chief Executive Officer & Director (LinkedIn Profile)
• Richard Allen Anderson, President & General Manager-North America Region
• Dror Bacher, Chief Operating Officer (LinkedIn Profile)
• Zvi Ben-David, Chief Financial Officer, Secretary & Treasurer
• Omar Manejwala, Chief Medical Officer

Who are some of DarioHealth's key competitors?

Some companies that are related to DarioHealth include AngioDynamics (ANGO), Treace Medical Concepts (TMCI), Sight Sciences (SGHT), Bioventus (BVS), Intersect ENT (XENT), Longview Acquisition Corp. II (LGV), Cardiovascular Systems (CSII), MiMedx Group (MDXG), CryoLife (CRY), OraSure Technologies (OSUR), SI-BONE (SIBN), Orthofix Medical (OFIX), Surmodics (SRDX), Vapotherm (VAPO) and Anika Therapeutics (ANIK).
View all of DRIO's competitors.

What other stocks do shareholders of DarioHealth own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include Aeterna Zentaris (AEZS), Vascular Biogenics (VBLT), Nano Dimension (NNDM), Pluristem Therapeutics (PSTI), CorMedix (CRMD), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL).

What is DarioHealth's stock symbol?

DarioHealth trades on the NASDAQ under the ticker symbol "DRIO."

Who are DarioHealth's major shareholders?

DarioHealth's stock is owned by many different retail and institutional investors. Top institutional shareholders include Collaborative Holdings Management LP (8.75%), BlackRock Inc. (4.55%), Geode Capital Management LLC (1.64%), Hsbc Holdings PLC (0.58%), GSA Capital Partners LLP (0.40%) and Goldman Sachs Group Inc. (0.33%). Company insiders that own DarioHealth stock include Adam K Stern, Dennis M Mcgrath, Dror Bacher, Erez Raphael and Oded Cohen.
View institutional ownership trends for DarioHealth.

Which institutional investors are selling DarioHealth stock?

DRIO stock was sold by a variety of institutional investors in the last quarter, including California State Teachers Retirement System, Royal Bank of Canada, and New York State Common Retirement Fund. Company insiders that have sold DarioHealth company stock in the last year include Dennis M Mcgrath, Dror Bacher, Erez Raphael, and Oded Cohen.
View insider buying and selling activity for DarioHealth or view top insider-selling stocks.

Which institutional investors are buying DarioHealth stock?

DRIO stock was purchased by a variety of institutional investors in the last quarter, including Collaborative Holdings Management LP, Hsbc Holdings PLC, GSA Capital Partners LLP, Geode Capital Management LLC, LPL Financial LLC, Millennium Management LLC, Panagora Asset Management Inc., and BlackRock Inc.. Company insiders that have bought DarioHealth stock in the last two years include Adam K Stern, and Erez Raphael.
View insider buying and selling activity for DarioHealth or or view top insider-buying stocks.

How do I buy shares of DarioHealth?

Shares of DRIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DarioHealth's stock price today?

One share of DRIO stock can currently be purchased for approximately $14.87.

How much money does DarioHealth make?

DarioHealth has a market capitalization of $246.49 million and generates $7.58 million in revenue each year. The company earns $-29.44 million in net income (profit) each year or ($4.15) on an earnings per share basis.

How many employees does DarioHealth have?

DarioHealth employs 133 workers across the globe.

What is DarioHealth's official website?

The official website for DarioHealth is www.mydario.com.

Where are DarioHealth's headquarters?

DarioHealth is headquartered at 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900.

How can I contact DarioHealth?

DarioHealth's mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The company can be reached via phone at (833) 914-3796, via email at [email protected], or via fax at 972-4770-4059.